Developing a novel partial epigenetic reprogramming (PER) platform targeting the underlying mechanisms of aging. FDA cleared the first-ever human trial of their epigenetic reprogramming therapy (ER-100) in early 2026, targeting optic neuropathies. *Catalogued by Claude* On this page you can view the company profile, browse linked jobs, products, posts, and ventures, inspect verification and contact details, follow related identity links.